ARTICLE | Company News
AstraZeneca, Aegerion deal
November 10, 2014 8:00 AM UTC
AstraZeneca will divest worldwide rights to develop and commercialize Myalept metreleptin for injection outside of three Asian territories to Aegerion for $325 million up front. AZ said the divestmen...